Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of ischemic stroke in Han Chinese of eastern China☆

Gnnn Wng, Yo Wng, Ho Sun, Weijun Co, Jing Zhng, Hng Xio, Jinsong Zhng*

aEmergency Center, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China;

bLaboratory of Neurotoxicology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 210029, China.Received 08 June 2011, Revised 02 August 2011, Accepted 12 August 2011

INTRODUCTION

Stroke is a common neurological disease and one of the leading causes of severe disability and death in China[1]. The majority of strokes are of ischemic origin with an atherothrombotic trigger, accounting for 80% of all strokes[2]. Ischemic stroke is a complex multifactorial and polygenic disorder that is thought to result from interactions between an individual's genetic background and various environmental factors. Atherothrombosis is considered to be the main cause[3]. A previous study had established age, sex, obesity, smoking, hypertension, diabetes, and dyslipidemia as reliable stroke risk predictors[4]. However, these conventional risk factors do not fully account for the overall risk of stroke. Evidences from twins, family, and animal studies have consistently suggested a genetic contribution to the risk of ischemic stroke[5].

Given that both systemic and local inflammatory processes are implicated in the etiology of ischemic cerebrovascular disease and in the pathophysiology of cerebral ischemia[6], polymorphisms of proinflammatory genes may contribute to the increase of susceptibility to ischemic stroke. A previous study highlighted the implication of single nucleotide polymorphisms (SNPs) and at-risk haplotypes in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene, conferring an increased risk of suffering from stroke in the Icelandic population through genome-wide linkage scan[7].

The human ALOX5AP gene is located on chromosome 13q12-13, including the 5 known exons and introns. It encodes 5-lipoxygenase-activating protein (FLAP or ALOX5AP), which is a regulator of the leukotriene (LT) biosynthetic pathway[7]. LT biosynthetic pathway comprises a family of arachidonic acid metabolites, which play an important role in the pathogenesis of atherosclerosis and inflammatory diseases, including ischemic stroke. In this biosynthetic pathway, unesterified arachidonic acid is converted to leukotriene A4 (LTA4) by the action of 5-lipoxygenase (5-LO) and its activating protein ALOX5AP. The unstable epoxide LTA4 is further metabolized to leukotriene B4 (LTB4) or leukotriene C4 (LTC4) by LTA4 hydrolase (LTA4H) and LTC4 synthase (LTC4S), respectively. LTB4 and LTC4 are moved out of the cell and can exert their biologic influence through specific receptors in inflammatory cells[8]. Functional polymorphisms of LT-related genes (such as ALOX5AP) may thereby enhance the susceptibility to stroke. Genetic effects in the LT biosynthetic pathway could be an important contributor to the development of atherosclerosis and to an increasing risk of ischemic stroke through the formation of the proinflammatory LTB4 and/or through an increase in vascular permeability caused by cysteinyl leukotrienes (LTC4 and its metabolites LTD4, LTE4)[9].

In an attempt to investigate the contribution of genetic variations in the ALOX5AP gene to ischemic stroke in a Chinese Han population of eastern China, a case-control association study was carried out to clarify the involvement of ALOX5AP genetic polymorphisms as risk factors for the pathogenesis of ischemic stroke and its subtypes.

MATERIALS AND METHODS

Study subjects

A total of 690 unrelated patients with a clinical diagnosis of ischemic stroke (cases) were recruited from the First Affiliated Hospital of Nanjing Medical University (Nanjing) between January 2009 and December 2010. All subjects were genetically-unrelated ethnic Han Chinese from Jiangsu Province and surrounding regions in eastern China. Stroke was defined by the presence of a new focal neurological deficit, with an acute onset and with symptoms and signs persisting for more than 24 h[10]. Ischemic stroke was confirmed in all patients by computed tomography (CT) and/or magnetic resonance imaging (MRI) as well as ancillary diagnostic investigations including duplex ultrasonography of the carotid and vertebral arteries, echocardiography, MR-angiography, CTangiography and standardized blood tests.

Ischemic stroke cases were classified into four major subtypes according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification[11]by a physician reviewing original imaging and clinical reports. The TOAST subtypes include: 1) largeartery atherosclerosis (LAA); 2) small-artery occlusion (SAO), i.e. lacunar infarction; 3) cardioembolism (CE), and 4) others (including other etiologies, unknown causes, and multiple potential causes). The control group consisted of 767 unrelated individuals (controls) who were recruited simultaneously from the same geographical area as the cases. The controls had no clinical evidence of neurological diseases and were matched by age, sex, and ethnic origin. The controls included inpatients with minor illnesses (51.2%) and people undergoing annual medical examination (48.8%), free of neurovascular and cardiovascular history or family history of stroke, ascertained by direct interview before recruitment. Patients with a clinically known inflammatory, autoimmune or malignant disease were excluded from the study.

Information on demographic characteristics and other risk factors of the cases and controls was collected by investigators using the same structured questionnaire involving body mass index (BMI), smoking, alcohol consumption, family history, and history of hypertension, and diabetes. Smoking was defined as having smoked at least one cigarette per day for one year or more. Former smokers with more than five years of smoke cessation were not included[12]. Alcohol drinking was defined as at least one alcoholic drink in a week, alcohol consumption ≥50 mL and continuing for more than three months. Hypertension was defined as a systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg based on the average of the two blood pressure measurements, or a patient's self-reported history of hypertension or the use of antihypertensive drugs. Diabetes was diagnosed if fasting plasma glucose (FPG) ≥7.0 mmol/L or plasma glucose≥11.1 mmol/L at 2 h after a 75 g oral glucose challenge or random plasma glucose≥11.1 mmol/L or the patient was on anti-diabetic medications[13].

The study protocol was reviewed and approved by the Institutional Review Boards for Human Studies of Nanjing Medical University. Informed consent was obtained from all participants.

Clinical laboratory measurements

Whole venous blood samples were collected after at least 12 h of fasting. Fasting plasma glucose, total plasma cholesterol (TC), triglyceride (TG), highdensity lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), uric acid (UA), and lipoprotein(a) [Lp(a)] were measured using an automatic biochemical analyzer (AU5400, Olympus, Tokyo, Japan).

LTB4 production analysis

The enzyme-linked immunosorbent assay (ELISA) was performed to quantify LTB4 concentration in plasma of 45 controls and 33 ischemic stroke cases, using a R&D human LTB4 ELISA Kit protocol. One in twenty samples was analyzed in replicate to assess analytical precision.

SNP selection and genotyping

Genomic DNA was extracted from peripheral white blood cells using the phenol/chloroform method. DNA samples were stored at -20°C. According to the information from the NCBI SNP database and HapMap database, SNPs which had a minor allele frequency (MAF) ＞ 0.05 and those with previously reported significant associations were chosen[14]. Therefore, two SNPs (rs10507391 and rs12429692) were selected in the human ALOX5AP gene to determine the association between patients with ischemic stroke and controls in a Chinese Han population of eastern China. Characteristics of the investigated two SNPs are shown in Table 1.

Table 1 Characteristics of the investigated SNPs

The selected SNP genotypes were determined in all 1,457 subjects by the TaqMan system. PCR was conducted in ABI 9700 thermocyclers (Applied Biosystems, Inc., Foster City, CA, USA). The allelic discrimination and scoring of the genotypes were performed using the ABI 7900 HT Sequence Detection System (SDS). The ABI assay-by-design protocol was used. The probes and primers are provided in Table 2. In each 384-well plate, two reference samples and two negative controls were included for quality control. Ten percent of the samples were randomly selected to perform repeated assays, and greater than 95% call rates occurred to both SNPs.

Statistical analysis

EpiData 3.0 was used to establish the database. Deviation from the Hardy-Weinberg equilibrium (HWE) was tested by comparing the observed and expected genotype frequencies of the controls using the χ2test. All continuous variables were expressed as mean±SD and compared using the unpaired Student's t test, unless otherwise indicated. Categorical variables were assessed by the χ2test or Fisher's exact test. The haplotype frequencies were estimated with the program PHASE version 2.1, which used a Bayesian method[15]. Genotypes were assessed according to codominant, dominant, and recessive genetic models. Each genetic model was comprised of two groups: heterozygotes and variant homozygotes, respectively, vs wild-type homozygotes for the codominant model; the combined group of variant homozygotes and heterozygotes vs wild-type homozygotes for the dominant model; variant homozygotes vs the combined group of wildtype homozygotes and heterozygotes for the recessive model. The χ2test or Fisher's exact test, as appropriate, was used to compare the distribution of genotypes and alleles of SNPs, as well as haplotypes between the cases and controls. The multivariate logistic regression model was performed to exclude the effects of the possible confounding factors (including sex, age, BMI, hypertension, and diabetes) on the association between genetic variants and ischemic stroke. The odds ratios (ORs) and 95% confidence intervals (95%CIs) for the effects of genotypes on ischemic stroke risk were uncorrected for confounding variables in the χ2test and unadjusted Logistic regression, and were corrected for covariates in adjusted regression models.

Plasma LTB4 levels of the different genotypes in the cases and controls were compared using t test or ANOVA with P ＜ 0.05 considered as statistically significant.

Table 2 TaqMan probes and primers for genotyping ALOX5AP SNPs

All the statistical tests were performed using SPSS version 16.0 (SPSS Inc., Chicago, USA). A two-tailed P value ＜ 0.05 was considered significant.

RESULTS

Clinical characteristics of subjects

The demographic characteristics of the controls and ischemic stroke cases are presented in Table 3. The mean age was 67.87±9.52 years for the cases and 67.54±9.46 years for the controls; 59.7% cases and 54.1% controls were male. As expected, compared with the control group, the ischemic stroke group had a greater prevalence of the conventional risk factors including male, history of hypertension and diabetes, as well as significantly higher BMI, systolic and diastolic blood pressure, FPG, TC, TG, LDL-C, UA and Lp(a), and lower HDL-C. However, there were no significant differences in smoking and alcohol drinking between the two groups. In addition, varied TOAST-subtypes showed different risk factors.

Table 3 Demographic and clinical characteristics of the study population

Association between the ALOX5AP polymorphisms and ischemic stroke

The genotype distributions of the two SNPs in controls were consistent with the Hardy-Weinberg equilibrium (P ＞ 0.05). There were no significant differences in the genotypic distributions and allelic frequencies of rs10507391 and rs12429692 between the controls and the ischemic stroke cases or its subtypes (Table 4). Furthermore, as shown in Table 5, no evidence of association with ischemic stroke and its subtypes (data not shown) was found by using different genetic models for both SNPs. When stratification analysis was performed according to sex, age, BMI, hypertension, and diabetes, there was also no significant association of the two SNPs with ischemic stroke risk (Table 5). In addition, because of the two SNPs (rs10507391 and rs12429692) had shown strong linkage disequilibrium (LD) in the same block region of ALOX5AP (pairwise R2＞ 0.8) defined by the program Haploview version 4.2, we carried out haplotype analysis. However, compared with controls, no significant association was found with the risk of ischemic stroke (Table 7) and its TOAST-subtypes (data not shown) in terms of the haplotype frequencies.

Table 4 Genotypic distributions and allelic frequencies of rs10507391 and rs12429692

Table 5 Detailed association results of the SNPs between controls and ischemic stroke

Analysis of LTB4 levels

To determine whether individuals with ischemic stroke had greater activity of the LT biosynthetic pathway than controls, the production of LTB4 (a key product of this pathway) was measured in plasma isolated from ischemic stroke cases and controls. LTB4 production analysis was conducted in 45 controls and 33 ischemic stroke cases (Fig. 1). A significant difference in the mean levels of LTB4 could be observed between cases and controls (P = 0.000) with ischemic stroke cases showing higher levels (70.06±14.75 ng/L) than controls (57.34±10.93 ng/L). However, association between LTB4 levels and the rs10507391 genotype could be observed neither in the case group (P = 0.593) nor in the control group (P = 0.122). Moreover, LTB4 levels did not differ between cases (72.57±16.22 ng/L, n = 9) and controls (60.89±9.73 ng/L, n = 12) carrying the AA genotype (P = 0.057). But a significant difference was found in the mean levels of T allele carriers between ischemic stroke cases (69.13±14.26 ng/L, n = 24) and controls (56.04±11.19 ng/L, n = 33, P = 0.000).

Table 6 Stratified analysis of the association between rs10507391 genotypes and ischemic stroke risk

Table 7 Haplotype analysis of ischemic stroke

Fig. 1 Box plot of the LTB4 levels in controls and ischemic stroke cases according to their rs10507391 genotypes.

DISCUSSION

Since a genome-wide linkage analysis conducted by the deCODE group in an Icelandic population suggested that a four-SNP haplotype in the ALOX5AP gene conferred a nearly two times greater risk of stroke[7], several groups attempted to replicate the association of ischemic stroke with ALOX5AP variants. Genetic association studies in different populations were subsequently carried out. However, the results were controversial and conflicting. In particular, a significant association of ischemic stroke with ALOX5AP polymorphisms was found in Scottish[9], German[16], Chinese[14,17], white American[18], Japanese[19], British[20], Spanish, and Portuguese[21]populations, whereas no evidence of a significant association was reported in different American[22-24], Swedish[25,26], and Italian[27]cohorts.

The present study examined the association between variants of ALOX5AP and the risk of ischemic stroke in a Chinese Han population of eastern China. The investigated SNPs herein were selected on the basis of earlier reports, in which significant associations with ischemic stroke had been demonstrated. However, the results of this study suggested a lack of association between two SNPs in ALOX5AP and ischemic stroke risk. Several explanations are possible for such disparate results. There might be substantial genetic heterogeneity for ischemic stroke, leading to varied results in different study populations. Other population-specific genetic differences also might account for divergent results among ischemic stroke patients in different countries. Random chance might produce spurious positive associations in some populations and studies, but not in others[28]. To minimize the possible founder effect of some ethnic groups, further study is required to verify the validity of the association with new stroke population according to distinct ethnicity.

ALOX5AP participates in the initial steps of LT synthesis. Arachidonic acid is converted to LTA4 by the action of 5-LO and ALOX5AP. LTA4 is then metabolized either to proinflammatory LTB4 or to the vasoconstrictive and proinflammatory cysteinyl LTs[29].

The deCODE group detected that the amount of LTB4 synthesized by ionomycin-stimulated neutrophils from individuals with myocardial infarction was greater than that produced by those from control individuals. Furthermore, the observed difference in the release of LTB4 was largely accounted for by the fact that carriers of at-risk haplotype produce more LTB4 than non-carriers[7]. Although LTB4 production was not measured in cells from patients with ischemic stroke, a similar increase would be expected, given that at-risk haplotype of ALOX5AP showed similar association with myocardial infarction and ischemic stroke. Elevated levels of LTB4 might contribute to atherogenesis or plaque instability by promoting inflammation at atherosclerotic plaques, which supported the notion that increased activity of the LT pathway plays an important role in the development of myocardial infarction and ischemic stroke[30,31].

In the present study, higher plasma LTB4 levels were observed in ischemic stroke cases than in controls, and LTB4 levels did not depend on the genotype of rs10507391 in cases or controls, respectively. This might indicate that during the acute phase of ischemic stroke, LTB4 levels are increased probably as part of the inflammation process. The lack of association with the genotype in cases and controls could be due to a general increase in LTB4 levels, masking the effect of the polymorphism. In addition, the fact that T allele carriers in cases presented statistically higher LTB4 levels than in controls suggested that T allele was associated with high LTB4 levels. However, it is not consistent with the association result of the rs10507391 allelic frequency with ischemic stroke. This could be explained by additional variants in ALOX5AP that have not been investigated, or in other genes belonging to the LT pathway, which may account for up-regulation of the LTB4 response. Further studies are needed to search for other potential causative variants in ALOX5AP and other genes involved in the LT pathway.

This study also presents several limitations. First, the proportion of males in cases was higher than in controls (59.7% vs 54.1%). To reduce a possible sex stratification effect, subgroup analysis stratified by sex was conducted. Moreover, TOAST subtype analysis of ischemic stroke cases showed non-significant association with genetic variants in ALOX5AP, although varied risk factors and phenotypic differences among ischemic stroke are mainly related to different stroke etiologies. Second, the sample size in the present study (690 cases and 767 controls) might not be large enough to detect a small effect of potential low-penetrance SNPs. Additionally, there was possible selection bias since the controls were partly recruited from hospital. Third, each single susceptible polymorphism might only contribute to a modest effect; thus analysis of a single SNP could be confused by unstudied SNPs that influence the phenotype. The combined effects of multiple variants of a gene or multiple genes would capture more information about ischemic stroke risk and provide a more comprehensive evaluation of genetic contribution to the risk of ischemic stroke. Therefore, more studies are needed to demonstrate the gene-gene interactions affecting the susceptibility to ischemic stroke.

In conclusion, the present study investigated the role of variants of ALOX5AP in the risk of developing ischemic stroke, and suggested no association between the two SNPs and ischemic stroke risk in a Chinese Han population of eastern China. Racial differences in the frequencies of genotypes and alleles may account partly for the different association findings between studies. Moreover, carrying T allele of the rs10507391 variant was associated with higher plasma LTB4 levels, which may result in a more evident proinflammatory activity and progression of atherosclerosis. Further rigorous genetic association studies, designed for the investigation of gene-gene and gene-environment interactions, might produce more conclusive results about the genetics of ischemic stroke.

[1] Jia Q, Liu LP, Wang YJ. Stroke in China. Clin Exp Pharmacol Physiol 2010;37:259-64.

[2] Matarin M, Singleton A, Hardy J, Meschia J. The genetics of ischaemic stroke. J Intern Med 2010;267:139-55.

[3] Yamada Y, Ichihara S, Nishida T. Proinflammatory gene polymorphisms and ischemic stroke. Curr Pharm Des 2008;14:3590-600.

[4] Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, et al. Proportion of different subtypes of stroke in China. Stroke 2003;34:2091-6.

[5] Matarin M, Brown WM, Dena H, Britton A, De Vrieze FW, Brott TG, et al. Candidate gene polymorphisms for ischemic stroke. Stroke 2009;40:3436-42.

[6] Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke 2003;34:2518-32.

[7] Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;36: 233-9.

[8] Riccioni G, Bäck M, Capra V. Leukotrienes and atherosclerosis. Curr Drug Targets 2010;11:882-7.

[10] Zintzaras E, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a HuGE genedisease association review and meta-analysis. Am J Epidemiol 2009;169:523-32.

[9] Helgadottir A, Gretarsdottir S, St Clair D, Manolescu A, Cheung J, Thorleifsson G, et al. Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am J Hum Genet 2005;76:505-9.

[11] Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.

[13] Shen CD, Zhang WL, Sun K, Wang YB, Zhen YS, Hui RT. Interaction of genetic risk factors confers higher risk for thrombotic stroke in male Chinese: a multicenter case-control study. Ann Hum Genet 2007;71:620-9.

[14] Sun H, Wu H, Zhang J, Wang J, Lu Y, Ding H, et al. A tagging SNP in ALOX5AP and risk of stroke: a haplotype-based analysis among eastern Chinese Han population. Mol Biol Rep 2010;38:4731-8.

[12] Kelly TN, Gu D, Chen J, Huang JF, Chen JC, Duan X, et al. Cigarette smoking and risk of stroke in the Chinese adult population. Stroke 2008;39:1688-93.

[16] Lõhmussaar E, Gschwendtner A, Mueller JC, Org T, Wichmann E, Hamann G, et al. ALOX5AP gene and the PDE4D gene in a central European population of stroke patients. Stroke 2005;36:731-6.

[15] Stephens M, Donnelly P. A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003;73:1162-9.

[17] Zhang WL, Yang XM, Shi J, Sun K, Hui RT. Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort. Yi Chuan Xue Bao (in Chinese) 2006;33:678-84.

[19] Yamada Y, Kato K, Oguri M, Yoshida T, Yokoi K, Watanabe S, et al. Association of genetic variants with atherothrombotic cerebral infarction in Japanese individuals with metabolic syndrome. Int J Mol Med 2008; 21: 801-8.

[18] Kaushal R, Pal P, Alwell K, Haverbusch M, Flaherty M, Moomaw C, et al. Association of ALOX5AP with ischemic stroke: a population-based case-control study. Hum Genet 2007;121:601-7.

[20] Bevan S, Dichgans M, Wiechmann HE, Gschwendtner A, Meitinger T, Markus HS. Genetic variation in members of the leukotriene biosynthesis pathway confer an increased risk of ischemic stroke: a replication study in two independent populations. Stroke 2008;39:1109-14.

[21] Domingues-Montanari S, Fernández-Cadenas I, del Rio-Espinola A, Corbeto N, Krug T, Manso H, et al. Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case-control, meta-analysis and functional study. Cerebrovasc Dis 2010;29:528-37.

[22] Meschia JF, Brott TG, Brown RD, Crook R, Worrall BB, Kissela B, et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke. Ann Neurol 2005;58:351-61.

[23] Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 2006;37:2007-11.

[24] Lemaitre RN, Rice K, Marciante K, Bis JC, Lumley TS, Wiggins KL, et al. Variation in eicosanoid genes, nonfatal myocardial infarction and ischemic stroke. Atherosclerosis 2009;204:e58-63.

[25] Kostulas K, Gretarsdottir S, Kostulas V, Manolescu A, Helgadottir A, Thorleifsson G, et al. PDE4D and ALOX5AP genetic variants and risk for ischemic cerebrovascular disease in Sweden. J Neurol Sci 2007;263: 113-7.

[26] Lövkvist H, Smith JG, Luthman H, Höglund P, Norrving B, Kristoffersson U, et al. Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region. Eur J Hum Genet 2008;16:1117-25.

[27] Quarta G, Stanzione R, Evangelista A, Zanda B, Di Angelantonio E, Marchitti S, et al. Phosphodiesterase 4D and 5-lipoxygenase activating protein genes and risk of ischemic stroke in Sardinians. Eur J Hum Genet 2009; 17:1448-53.

[28] Markus HS, Alberts MJ. Update on genetics of stroke and cerebrovascular disease 2005. Stroke 2006;37:288-90.

[29] Evans JF, Ferguson AD, Mosley RT, Hutchinson JH. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72-8.

[30] Gulcher JR, Gretarsdottir S, Helgadottir A, Stefansson K. Genes contributing to risk for common forms of stroke. Trends Mol Med 2005;11:217-24.

[31] Bäck M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 2009;15:3116-32.